ArticleRheumatology international2020

Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.

Ennio G Favalli et al.PubMed ↗Publisher ↗

No numbers read from the abstract.